Risperidone - Mapi Pharma

Drug Profile

Risperidone - Mapi Pharma

Alternative Names: Risperidone LAI; Risperidone LAI - Mapi Pharma; Risperidone LAI+

Latest Information Update: 28 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mapi Pharma
  • Developer Jiangsu Nhwa Pharmaceutical; Mapi Pharma
  • Class Antineoplastics; Antipsychotics; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Schizophrenia
  • No development reported Bipolar disorders

Most Recent Events

  • 28 May 2018 No recent reports of development identified for preclinical development in Bipolar-disorders in China (IV, Injection)
  • 28 May 2018 No recent reports of development identified for preclinical development in Bipolar-disorders in Israel (IV, Injection)
  • 28 May 2018 No recent reports of development identified for preclinical development in Schizophrenia in Israel (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top